Total Funding
26
71
Total FundingSeed raised
Growth Score
-4 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
88474
GigaMune is a biotech firm focused on engineered TCR-Treg cell therapies for autoimmune diseases, including Type 1 Diabetes.
Mark Cobbold: Scientific Co-FounderPast Role: Massachusetts General Hospital, Associate Professor
Adam Adler: Co-FounderPast Role: GigaGen, Vice President of Research and Development
About the Company
GigaMune was founded as a spin-out from GigaGen in 2017. They are combining unique insight into T cell responses to tumors with massively parallel T cell receptor (TCR) discovery to develop the next generation of T cell therapies.
